Cost-per-responder analysis of guselkumab versus ixekizumab with the use of efficacy results from pivotal clinical trials in patients with moderate to severe plaque psoriasis

2018 ◽  
Vol 79 (3) ◽  
pp. AB88
2011 ◽  
Vol 22 (3) ◽  
pp. 138-143 ◽  
Author(s):  
Silas Martin ◽  
Steven R. Feldman ◽  
Matthias Augustin ◽  
Philippe Szapary ◽  
Brad Schenkel

Sign in / Sign up

Export Citation Format

Share Document